Segall Bryant & Hamill LLC Has $5.25 Million Stock Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Segall Bryant & Hamill LLC lessened its stake in ADMA Biologics, Inc. (NASDAQ:ADMA) by 12.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 306,352 shares of the biotechnology company’s stock after selling 44,987 shares during the quarter. Segall Bryant & Hamill LLC owned about 0.13% of ADMA Biologics worth $5,254,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in ADMA Biologics by 1.3% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 50,466 shares of the biotechnology company’s stock valued at $865,000 after acquiring an additional 645 shares during the last quarter. Oregon Public Employees Retirement Fund boosted its position in shares of ADMA Biologics by 1.3% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 55,600 shares of the biotechnology company’s stock worth $954,000 after purchasing an additional 700 shares during the last quarter. Mutual of America Capital Management LLC grew its stake in shares of ADMA Biologics by 2.1% during the fourth quarter. Mutual of America Capital Management LLC now owns 35,807 shares of the biotechnology company’s stock worth $614,000 after purchasing an additional 751 shares during the period. Maryland State Retirement & Pension System lifted its stake in ADMA Biologics by 1.1% in the fourth quarter. Maryland State Retirement & Pension System now owns 79,607 shares of the biotechnology company’s stock valued at $1,365,000 after buying an additional 897 shares during the period. Finally, GAMMA Investing LLC boosted its holdings in ADMA Biologics by 106.6% during the fourth quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock worth $32,000 after buying an additional 967 shares during the last quarter. 75.68% of the stock is owned by institutional investors.

ADMA Biologics Stock Up 2.9 %

NASDAQ:ADMA opened at $20.28 on Friday. The stock has a market cap of $4.79 billion, a price-to-earnings ratio of 72.43 and a beta of 0.60. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The stock has a 50-day moving average price of $17.05 and a two-hundred day moving average price of $18.13. ADMA Biologics, Inc. has a 1 year low of $5.90 and a 1 year high of $23.64.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $25.00 price target on shares of ADMA Biologics in a research note on Tuesday, March 4th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.